PM8002 is a bispecific antibody drug targeting PD-L1 and VEGF-A, and, in a phase II study, PM8002 combined with paclitaxel showed 81.8% DCR, 72.7% ORR, and up to 5.5 months mPFS in the second-line SCLC (n = 27) who failed in first-line platinum-based chemotherapy with or without ICIs, implying encouraging anti-tumor activity. Here, CD274 is linked to neoplasm.